Advanced NanoTherapies Raises Over $31M in Series B Funding

The round also saw participation from the T45 Fund and other new and existing investors.

The company plans to use the funding to expand manufacturing, obtain U.S. Investigational Device Exemption (IDE) approvals, advance coronary clinical trials, and develop applications for below-the-knee peripheral treatments.

Advanced NanoTherapies is developing a next-generation vascular treatment platform using a dual-drug (paclitaxel and sirolimus) nanoparticle-coated balloon. The goal is to improve treatment effectiveness and create a more consistent, long-lasting vessel response compared to earlier single-drug drug-coated balloons.

Advanced NanoTherapies’s technology is exclusively licensed from the Cleveland Clinic and is designed as a drug-agnostic, fully biodegradable platform for use in coronary, peripheral, and other vascular applications.

"This financing validates the strength of ANTs platform, and the momentum built across science, clinical execution, and regulatory readiness," said Brian R. Smith, Managing Director at S3 Ventures. "With clinical experience across two coronary studies and a clear US regulatory path, ANT is well-positioned to move toward pivotal execution and to bring a truly differentiated therapy to patients needing better options."

"SirPlux Duo enables dual drug delivery with controlled cellular uptake and sustained tissue retention, generating higher potency at lower doses, reducing downstream particulate burden, and preserving future treatment options across coronary, and peripheral vascular disease," said Azeem Latib, MD, Medical Director, Structural Heart Intervention, Montefiore Einstein. "The creation of a new DCB category using two rather than one drug is a leapfrogging moment in vascular intervention, providing sustainable clinical outcomes that are non-inferior to those of drug eluting stents while maintaining the intervention strategy of leaving nothing behind."

Read More:Kish Bancorp, Inc. Welcomes Tracy Wilkinson as Chief Credit Officer

"This financing milestone arrives at a pivotal moment in vascular intervention. First-generation single drug DCBs are gaining traction in the U.S. market. Still, they continue to expose the limitations of passive crystalline drug delivery," said Marwan Berrada-Sounni, CEO of ANT "ANT is uniquely positioned to advance the field through a differentiated nanoparticle-enabled approach to local vascular therapy, which is long overdue."

"Restenosis after PCI (percutaneous coronary intervention) continues to be a meaningful clinical challenge, largely driven by cell proliferation at the treatment site. This novel platform aims to deliver two drugs simultaneously to the lesion site using functionalized nanoparticles, enabling sustained local drug retention at lower doses," said Rishi Puri, MD, interventional cardiologist, Cleveland Clinic.

About Advanced NanoTherapies

Advanced NanoTherapies, a T45 Labs portfolio company founded in 2018, is developing a nanoparticle based platform for localized dual-drug delivery during catheter based vascular procedures. Its lead program, SirPlux Duo, represents a new approach to drug coated balloon therapy by delivering two complementary drugs directly to the treatment site for more controlled and sustained vascular effects.

Read More:Nubank Appoints Rob Livingston as Chief Financial Officer